ImmVira is a biotechnology company focused on development of new generation novel drug vectors driven by clinical benefits in oncology and non-oncology fields. Leveraging naturally evolved delivery mechanisms and proprietary precise gene engineering technology, our products include replicating and non-replicating herpes simplex virus vector and drug delivery exosome.
We are a global leader in next-generation vector development for precise, potent and safe treatments, with multiple clinical-stage and IND-enabling assets.